A Phase 3 interventional study of everolimus and cyclosporine in de Novo Kidney Transplant Recipients and Renal Transplantation, sponsored by Novartis. Completed at 28 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-07-19.
Sponsored by Novartis · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will compare the following immunosuppressive regimens in recipients of kidney transplantation: A) everolimus, cyclosporine and steroids given once-a-day; B) everolimus and cyclosporine given twice a day with steroid withdrawal; C) everolimus, cyclosporine given twice a day and continuous steroids. The purpose of this study is to evaluate regimens A and B in comparison with the control group (group C) for efficacy, using as main endpoint the treatment failure rate, a composite endpoint including death, graft loss, BPAR and lost to follow-up between randomization and Month 12.
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Exclusion criteria at screening (pre-transplantation, Visit 1):
Additional exclusion criteria post-transplantation (Visit 2):
To avoid any possible influence of the confounding factors on the results of this study additional exclusion criteria at randomization were (Visit 5, Month 3):
poor compliance to prescribed treatments
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Everolimus: in patients randomized to Group A before Amendment 1 approval, from the day following randomization, the whole daily dose of everolimus was taken in the morning, at the same time of the CsA and steroid dosing. At the Rand+1W visit, the everolimus dose was adjusted to reach and maintain everolimus blood levels between 5 and 8 ng/mL until end of Month 12. Cyclosporine: in patients randomized to Group A before Amendment 1 approval, from the day following randomization, the whole cyclosporine daily dose was taken in the morning. The dose was then adjusted to maintain C2 levels between 350 and 700 ng/mL. Prednisone: In patients randomized to Group A before Amendment 1 approval, the dose of prednisone was kept stable at 5 mg/day in the morning.
Drug: everolimus · Drug: cyclosporine · Drug: Prednison (continuous steroids)
Everolimus: after randomization the everolimus dose was adjusted, if necessary, to maintain a C0 within 6-10 ng/mL until M12. Cyclosporine:after randomization the cyclosporine dose was adjusted to maintain CsA C2 levels within 300-500 ng/mL until M12. Prednisone: starting from Visit 5 (day 90 ± 28 days), oral prednisone was tapered until complete stop. It was recommended to taper prednisone by 1 mg/week until complete stop in 5 to 6 weeks.
Drug: everolimus · Drug: cyclosporine · Drug: Prednison (continuous steroids)
Everolimus: after randomization the everolimus dose was adjusted, if necessary, in order to maintain a C0 within 6-10 ng/mL until M12. Cyclosporine: after randomization the cyclosporine dose was gradually adjusted to reach and maintain C2 blood levels of 200-450 ng/mL between Month 6 and Month 12. Prednisone: the dose of prednisone was kept stable at 5 mg/day in the morning.
Drug: everolimus · Drug: cyclosporine · Drug: Prednison (continuous steroids)
NRP defined in whom a renal transplantation was performed, received at least one dose of study drug (everolimus) but who did not qualify for randomization at Visit 5, Day 90. This group was addressed as "not randomized patients" (NRP) and described with respect to baseline characteristics, treatment and outcome variables.
Drug: everolimus
Everolimus (Certican®) was provided in blisters containing tablets of 0.25 mg and 0.75 mg. Everolimus was initiated within 48 hours after graft reperfusion and it was administered orally.
Also known as: Certican®)
Cyclosporine for microemulsion (CsA, Sandimmun® Neoral®) was coadministered with everolimus at the same time of the day. CsA was available in alu-alu blisters containing soft gelatine capsules of 100 mg, 50 mg, 25 mg and 10 mg. Oral solution, as bottles containing 50 mL of solution (100 mg/mL) has been provided and used in case the drug had been administered to patients by nasogastric tube immediately after transplant.
Also known as: CsA, Sandimmun® Neoral®
continuous steroids
Treatment Failure Rate
Occurrence or not of treatment failure in each patient. Treatment failure was defined as a composite endpoint of biopsy-proven acute rejection (a biopsy graded IA, IB, IIA, IIB or III according to Banff '97 grading with 2007 update), graft loss, death or lost to follow-up occurring after randomization (V5) and within M12 (V9).
Time frame: Between randomization (Month 3) and Month 12
Changes in the Estimated Glomerular Filtration Rate (eGFR) Between Randomization (Month 3) and Month 12
eGFR by Nankivell, in terms of descriptive statistics and change vs randomization visit - to compare the changes in the estimated GFR (Nankivell) between randomization and Month 12 in the steroid withdrawal group (Group B) to the change observed in the standard twice-a-day group (Group C), for non-inferiority
Time frame: Month 3 to Month 12
Biopsy Proven Acute Rejection (BPAR) Rate Between Randomization and Month 12
Occurrence of BPAR (after randomization) between arm B (steroid withdrawal group) and arm c (standard twice-a-day group). BPAR was defined as a biopsy graded IA, IB, IIA, IIB, or III according to Banff 1997 grading with 2007 update.
Time frame: Month 3 to Month 12
Number of Participants With Graft and Patient Survival After Randomization
Graft Survival, calculated from the date of transplantation to the date of irreversible graft failure signified by return to long-term retransplantation or the date of the last follow-up during the period when the transplant was still functioning or to the date of death. Patient survival, calculated from the date of transplantation to the date of death or the date of the last follow-up.
Time frame: Month 3 to Month 12
Change in Estimated Creatine Clearance
At each visit, estimated creatinine clearance was measured in the local laboratory to analyze the evolution of the renal function. The following indirect measures of renal function were computed: estimated creatinine clearance according to Cockcroft and Gault formula and MDRD formula.
Time frame: M3, M12
Change in Serum Creatinine
Serum creatinine (a blood measurement) is an important indicator of renal health because it is an easily-measured by-product of muscle metabolism. Measuring serum creatinine is a simple test and it is the most commonly used indicator of renal function.
Time frame: M3, M12
A total of 332 patients were screened. 330 were pre-randomized, 2 were not. Additionally, 2 pts were not treated which made the safety/ITT population 328. Of the 328, 184 were randomized and 144 were not. Of the 144, 70 dropped before day 90 \& 74 completed the pre-rand period but were not randomized because they were not eligible for randomization.
| Milestone | Pre-randomized: Not-randomization Patients (NRP) | Randomized: Group A - Once-a-day Regimen | Randomized: Group B - Steroid Withdrawal Group | Randomized: Group C - Standard Twice-a-day Group |
|---|---|---|---|---|
| Started | 328 | 0 | 0 | 0 |
| Completed | 184 | 0 | 0 | 0 |
| Not completed | 144 | 0 | 0 | 0 |
| Withdrew: Did not meet inclusion criteria | 144 | 0 | 0 | 0 |
| Milestone | Pre-randomized: Not-randomization Patients (NRP) | Randomized: Group A - Once-a-day Regimen | Randomized: Group B - Steroid Withdrawal Group | Randomized: Group C - Standard Twice-a-day Group |
|---|---|---|---|---|
| Started | 0 | 45 | 68 | 71 |
| Completed | 0 | 42 | 60 | 68 |
| Not completed | 0 | 3 | 8 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 0 |
| Withdrew: Administrative problems | 0 | 1 | 6 | 2 |
| Withdrew: Graft loss | 0 | 1 | 0 | 0 |
Occurrence or not of treatment failure in each patient. Treatment failure was defined as a composite endpoint of biopsy-proven acute rejection (a biopsy graded IA, IB, IIA, IIB or III according to Banff '97 grading with 2007 update), graft loss, death or lost to follow-up occurring after randomization (V5) and within M12 (V9).
| Participants | Group A - Once-a-day Regimen | Group B - Steroid Withdrawal Group | Group C - Standard Twice-a-day Group |
|---|---|---|---|
| Treatment Failure Rate | 3 | 10 | 2 |
eGFR by Nankivell, in terms of descriptive statistics and change vs randomization visit - to compare the changes in the estimated GFR (Nankivell) between randomization and Month 12 in the steroid withdrawal group (Group B) to the change observed in the standard twice-a-day group (Group C), for non-inferiority
| mL/min | Group B - Steroid Withdrawal Group | Group C - Standard Twice-a-day Group |
|---|---|---|
| Changes in the Estimated Glomerular Filtration Rate (eGFR) Between Randomization (Month 3) and Month 12 | -1.7 ± 9.5 | 2.5 ± 10.6 |
Occurrence of BPAR (after randomization) between arm B (steroid withdrawal group) and arm c (standard twice-a-day group). BPAR was defined as a biopsy graded IA, IB, IIA, IIB, or III according to Banff 1997 grading with 2007 update.
| Participants | Group B - Steroid Withdrawal Group | Group C - Standard Twice-a-day Group |
|---|---|---|
| Biopsy Proven Acute Rejection (BPAR) Rate Between Randomization and Month 12 | 9 | 2 |
Graft Survival, calculated from the date of transplantation to the date of irreversible graft failure signified by return to long-term retransplantation or the date of the last follow-up during the period when the transplant was still functioning or to the date of death. Patient survival, calculated from the date of transplantation to the date of death or the date of the last follow-up.
| Participants | Group B - Steroid Withdrawal Group | Group C - Standard Twice-a-day Group |
|---|---|---|
| Number of Participants With Graft and Patient Survival After Randomization | 68 | 71 |
At each visit, estimated creatinine clearance was measured in the local laboratory to analyze the evolution of the renal function. The following indirect measures of renal function were computed: estimated creatinine clearance according to Cockcroft and Gault formula and MDRD formula.
| mL/min | Group B - Steroid Withdrawal Group | Group C - Standard Twice-a-day Group |
|---|---|---|
| Using Cockcroft and Gault model @ month 3 | 64.8 ± 21.8 | 63.0 ± 20.9 |
| Using Cockcroft and Gault model @ month 12 | 62.3 ± 21.4 | 66.9 ± 24.7 |
| Using MDRD-4 formular @ month 3 | 57.9 ± 20.0 | 58.8 ± 21.8 |
| Using MDRD-4 formular @ month 12 | 53.6 ± 18.9 | 61.8 ± 23.1 |
Serum creatinine (a blood measurement) is an important indicator of renal health because it is an easily-measured by-product of muscle metabolism. Measuring serum creatinine is a simple test and it is the most commonly used indicator of renal function.
| mg/dL | Group B - Steroid Withdrawal Group | Group C - Standard Twice-a-day Group |
|---|---|---|
| Serum Creatinine @ month 3 | 1.4 ± 0.4 | 1.4 ± 0.4 |
| Serum Creatinine @ month 12 | 1.5 ± 0.5 | 1.4 ± 0.5 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Not Randomized Population (NRP) | — | 65/144 (45.1%) | 108/144 (75%) |
| Group A - Once-a-day Regimen | — | 18/45 (40%) | 35/45 (77.8%) |
| Group B - Steroid Withdrawal Group | — | 24/68 (35.3%) | 56/68 (82.4%) |
| Group C - Standard Twice-a-day Group | — | 25/71 (35.2%) | 57/71 (80.3%) |
| Event | Not Randomized Population (NRP) | Group A - Once-a-day Regimen | Group B - Steroid Withdrawal Group | Group C - Standard Twice-a-day Group |
|---|---|---|---|---|
| Transplant rejectionImmune system disorders | 11/144 | 0/45 | 6/68 | 2/71 |
| Urinary tract infectionInfections and infestations | 0/144 | 2/45 | 6/68 | 0/71 |
| Renal impairmentRenal and urinary disorders | 5/144 | 1/45 | 4/68 | 6/71 |
| Blood creatinine increasedInvestigations | 5/144 | 2/45 | 5/68 | 3/71 |
| LymphoceleVascular disorders | 2/144 | 3/45 | 2/68 | 1/71 |
| HyperpyrexiaGeneral disorders | 0/144 | 0/45 | 4/68 | 0/71 |
| Graft lossInjury, poisoning and procedural complications | 7/144 | 0/45 | 0/68 | 0/71 |
| PyrexiaGeneral disorders | 2/144 | 2/45 | 0/68 | 0/71 |
| Kidney transplant rejectionImmune system disorders | 2/144 | 2/45 | 1/68 | 1/71 |
| Toxicity to various agentsInjury, poisoning and procedural complications | 4/144 | 0/45 | 3/68 | 1/71 |
| Event | Not Randomized Population (NRP) | Group A - Once-a-day Regimen | Group B - Steroid Withdrawal Group | Group C - Standard Twice-a-day Group |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 53/144 | 10/45 | 23/68 | 13/71 |
| HyperlipidaemiaMetabolism and nutrition disorders | 16/144 | 12/45 | 20/68 | 18/71 |
| Oedema peripheralGeneral disorders | 7/144 | 6/45 | 16/68 | 9/71 |
| Urinary tract infectionInfections and infestations | 25/144 | 7/45 | 14/68 | 16/71 |
| HypertensionVascular disorders | 25/144 | 8/45 | 11/68 | 14/71 |
| Complications of transplanted kidneyInjury, poisoning and procedural complications | 22/144 | 7/45 | 6/68 | 8/71 |
| Blood creatinine increasedInvestigations | 6/144 | 6/45 | 5/68 | 3/71 |
| HypokalaemiaMetabolism and nutrition disorders | 18/144 | 6/45 | 7/68 | 6/71 |
| DiarrhoeaGastrointestinal disorders | 7/144 | 3/45 | 8/68 | 1/71 |
| HypocalcaemiaMetabolism and nutrition disorders | 15/144 | 5/45 | 7/68 | 3/71 |
Safety Population: The Safety Population (SAF population) includes all patients who signed an informed consent, performed renal transplantation and received at least one dose of study drug (everolimus).
| Age, Continuous(years) | Not Randomized Population (NRP) | Group A - Once-a-day Regimen | Group B - Steroid Withdrawal Group | Group C - Standard Twice-a-day Group | Total |
|---|---|---|---|---|---|
| Mean | 52.9 ± 11.5 | 46.6 ± 13.7 | 48.5 ± 11.6 | 49.2 ± 13.0 | 50.3 ± 12.3 |
| Sex: Female, Male(Participants) | Not Randomized Population (NRP) | Group A - Once-a-day Regimen | Group B - Steroid Withdrawal Group | Group C - Standard Twice-a-day Group | Total |
|---|---|---|---|---|---|
| Female | 56 | 15 | 22 | 20 | 113 |
| Male | 88 | 30 | 46 | 51 | 215 |
| Race/Ethnicity, Customized(Participants) | Not Randomized Population (NRP) | Group A - Once-a-day Regimen | Group B - Steroid Withdrawal Group | Group C - Standard Twice-a-day Group | Total |
|---|---|---|---|---|---|
| Caucasian | 139 | 44 | 68 | 67 | 318 |
| Black | 3 | 0 | 0 | 1 | 4 |
| Oriental | 1 | 1 | 0 | 0 | 2 |
| Other | 1 | 0 | 0 | 3 | 4 |
| Smoking Status(Participants) | Not Randomized Population (NRP) | Group A - Once-a-day Regimen | Group B - Steroid Withdrawal Group | Group C - Standard Twice-a-day Group | Total |
|---|---|---|---|---|---|
| No | 119 | 41 | 58 | 56 | 274 |
| Yes | 16 | 2 | 2 | 2 | 22 |
| Missing | 9 | 2 | 8 | 13 | 32 |
| BMI(kg/m^2) | Not Randomized Population (NRP) | Group A - Once-a-day Regimen | Group B - Steroid Withdrawal Group | Group C - Standard Twice-a-day Group | Total |
|---|---|---|---|---|---|
| Mean | 24.6 ± 3.4 | 24.9 ± 3.6 | 24.1 ± 3.3 | 24.2 ± 3.6 | 24.4 ± 3.4 |
| Female reproductive status(Participants) | Not Randomized Population (NRP) | Group A - Once-a-day Regimen | Group B - Steroid Withdrawal Group | Group C - Standard Twice-a-day Group | Total |
|---|---|---|---|---|---|
| Childbearing potential with contraceptive protecti | 11 | 8 | 12 | 4 | 35 |
| Surgically sterilised | 2 | 0 | 2 | 0 | 4 |
| Postmenopausal | 43 | 7 | 8 | 16 | 74 |
| Result of HCG pregnancy screen - Negative(Participants) | Not Randomized Population (NRP) | Group A - Once-a-day Regimen | Group B - Steroid Withdrawal Group | Group C - Standard Twice-a-day Group | Total |
|---|---|---|---|---|---|
| Negative | 10 | 6 | 12 | 4 | 32 |
| Missing | 46 | 9 | 10 | 16 | 81 |
The record gives a start of Apr 2009, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2013, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Everolimus